Thrombin stimulates increased plasminogen activator inhibitor-1 release from liver compared to lung endothelium

J Surg Res. 2018 May:225:1-5. doi: 10.1016/j.jss.2017.12.017. Epub 2018 Jan 5.

Abstract

Background: Plasminogen activator inhibitor-1 (PAI-1) is a major regulator of the fibrinolytic system, covalently binding to tissue plasminogen activator and blocking its activity. Fibrinolysis shutdown is evident in the majority of severely injured patients in the first 24 h and is thought to be due to PAI-1. The source of this PAI-1 is thought to be predominantly endothelial cells, but there are known organ-specific differences, with higher levels thought to be in the liver. Thrombin generation is also elevated in injured patients and is a potent stimulus for PAI-1 release in human umbilical endothelial cells. We hypothesize that thrombin induces liver endothelial cells to release increased amounts of PAI-1, versus pulmonary endothelium, consisting of both stored PAI-1 and a larger contribution from de novo PAI-1 synthesis.

Methods: Human liver sinusoidal endothelial cells (LSECs) and human microvascular lung endothelial cells (HMVECs) were stimulated in vitro ± thrombin (1 and 5 IU/mL) for 15-240 min, the supernatants were collected, and PAI-1 was measured by enzyme-linked immunosorbent assays. To elucidate the PAI-1 contribution from storage versus de novo synthesis, cycloheximide (10 μg/mL) was added before thrombin in separate experiments.

Results: While both LSECs and HMVECs rapidly stimulated PAI-1 release, LSECs released more PAI-1 than HMVECs in response to high-dose thrombin, whereas low-dose thrombin did not provoke immediate release. LSECs continued to release PAI-1 over the ensuing 240 min, whereas HMVECs did not. Cycloheximide did not inhibit early PAI-1 release from LSECs but did at the later time points (30-240 min).

Conclusions: Thrombin elicits increased amounts of PAI-1 release from liver endothelium compared with lung, with a small presynthesized stored contribution and a later, larger increase in PAI-1 release via de novo synthesis. This study suggests that the liver may be an important therapeutic target for inhibition of the hypercoagulable surgical patient and the associated complications that result.

Keywords: Endothelium; Fibrinolysis; Liver; Lung; Plasminogen activator inhibitor-1.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cells, Cultured
  • Cycloheximide / pharmacology
  • Endothelial Cells / metabolism*
  • Endothelium, Vascular / cytology
  • Endothelium, Vascular / metabolism
  • Enzyme-Linked Immunosorbent Assay
  • Fibrinolysis / physiology*
  • Humans
  • Liver / cytology
  • Liver / metabolism*
  • Lung / cytology
  • Lung / metabolism*
  • Plasminogen Activator Inhibitor 1 / analysis
  • Plasminogen Activator Inhibitor 1 / metabolism*
  • Protein Biosynthesis / drug effects
  • Protein Synthesis Inhibitors / pharmacology
  • Thrombin / metabolism*
  • Thrombosis / etiology
  • Thrombosis / physiopathology
  • Tissue Plasminogen Activator / metabolism
  • Wounds and Injuries / complications
  • Wounds and Injuries / physiopathology

Substances

  • Plasminogen Activator Inhibitor 1
  • Protein Synthesis Inhibitors
  • SERPINE1 protein, human
  • Cycloheximide
  • Thrombin
  • PLAT protein, human
  • Tissue Plasminogen Activator